



## **Aduro Biotech to Present at the 36th Annual J.P. Morgan Healthcare Conference**

January 4, 2018

BERKELEY, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 36<sup>th</sup> Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 11, 2018, at 9:00 am Pacific Time.

To access the live webcast and subsequent archived recording of this and other company presentations, please visit Aduro's website at [www.aduro.com](http://www.aduro.com).

### **About Aduro**

Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's STING Pathway Activator platform is designed to activate the STING receptor in immune cells, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in both a Phase 1 monotherapy study as well as a Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor. Aduro's B-select monoclonal antibody platform is comprised of a number of immune modulating assets in research and development, including BION-1301, an anti-APRIL antibody. Aduro's pLADD program is based on proprietary attenuated strains of Listeria that have been engineered to express tumor neoantigens that are specific to an individual patient's tumor. Other Listeria strains for lung and prostate cancers are being advanced by a partner. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit [www.aduro.com](http://www.aduro.com).

### Contact:

Alexandra Santos  
Corporate Affairs & Investor Relations  
510 809 9231

### Media Contact:

Aljanae Reynolds  
510 809 2452  
[press@aduro.com](mailto:press@aduro.com)



Source: Aduro Biotech, Inc.